Long-term efficacy and safety of osilodrostat in patients with Cushing’s disease: results from the LINC 4 study extension

Long-term efficacy and safety of osilodrostat in patients with Cushing’s disease: results from the LINC 4 study extension

ObjectiveTo evaluate the long-term efficacy and safety of osilodrostat in patients with Cushing’s disease.MethodsThe multicenter, 48-week, Phase III LINC 4 clinical trial had an optional extension period that was initially intended to continue to week 96. Patients could continue in the extension unt...

Full description

Bibliographic Details
Main Authors: Mônica Gadelha, Peter J. Snyder, Przemysław Witek, Marie Bex, Zhanna Belaya, Adina F. Turcu, Richard A. Feelders, Anthony P. Heaney, Michaela Paul, Alberto M. Pedroncelli, Richard J. Auchus
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Endocrinology
Subjects:
Cushing’s disease
osilodrostat
hypercortisolism
11β-hydroxylase
long-term treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1236465/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1236465/full

Similar Items